BOC Sciences delivers professional antimicrobial peptide (AMP) synthesis services backed by deep expertise in solid-phase peptide synthesis (SPPS), complex sequence handling, disulfide bond formation, and a wide range of structural modifications. From linear α-helical AMPs to multi-disulfide β-sheet defensins and lipidated antifungal peptides, we support research teams in anti-infective drug discovery, biofilm inhibition, host defense peptide studies, and structure-activity relationship (SAR) programs with reliable, well-characterized peptide products and comprehensive analytical documentation.
Antimicrobial peptide synthesis is the chemical or chemoenzymatic production of naturally occurring or designed peptides that exhibit direct antimicrobial activity against bacteria, fungi, viruses, or parasites. These peptides — typically 10 to 50 amino acids in length — often feature cationic and amphipathic sequences, disulfide-stabilized folds, or non-proteinogenic modifications such as D-amino acids, lipidation, and cyclization. Chemical synthesis, most commonly peptide synthesis via Fmoc-based SPPS, enables precise control over sequence, stereochemistry, and modification patterns, producing homogeneous AMPs suitable for in vitro and in vivo functional evaluation. Synthesis also facilitates the incorporation of unnatural building blocks, fluorescent labels, and structural elements that are inaccessible through recombinant expression, making it the method of choice for SAR-driven AMP optimization and analog library construction.
We synthesize antibacterial peptides and analog series for projects involving bacterial membranes, intracellular targets, biofilms, and resistant-strain research.
BOC Sciences prepares antifungal peptides for membrane-interaction, cell-wall, biofilm, and peptide optimization studies across research-stage fungal models.
Our antiviral peptide synthesis services support sequences designed to study viral attachment, membrane fusion, entry, replication-associated interactions, and host-defense mechanisms.
We prepare antiparasitic peptide candidates and analogs for research on protozoal, helminth, and parasite-membrane interactions.
BOC Sciences helps research teams move from AMP sequence design and modification planning to SPPS assembly, oxidative folding, purification, and fully characterized peptide delivery — all within a single coordinated workflow.
BOC Sciences supports antimicrobial peptides with diverse secondary structures and molecular architectures. Sequence composition, folding requirements, modification sites, solubility, and downstream research goals are considered together when defining the synthesis route.
| Structural Type | Representative Structural Features | Available Modification and Synthesis Options |
| α-Helical Peptides | Amphipathic helices with spatially separated cationic and hydrophobic faces; often linear in aqueous solution and structured in membrane-like environments. | N- and C-terminal capping, residue scanning, D-amino acid substitution, helix stabilization, lipidation, PEG spacing, and fluorescent or affinity labeling. |
| β-Sheet Peptides | Antiparallel or parallel β-strands frequently stabilized by disulfide bonds, hydrogen-bonding networks, or compact cysteine-rich frameworks. | Orthogonal cysteine protection, controlled oxidative folding, disulfide-pattern variants, loop substitution, terminal modification, and site-selective labeling. |
| β-Hairpin and Loop Peptides | Turn-containing structures that position two short strands or constrained loops within compact membrane-interacting or target-binding motifs. | Turn optimization, lactam or disulfide constraints, head-to-tail or side-chain cyclization, D-amino acid turns, and loop-focused analog libraries. |
| Mixed α/β Peptides | Structured peptides combining helical segments, β-strands, loops, and disulfide-stabilized regions within one compact sequence. | Segment-specific protection, sequential disulfide formation, fragment ligation, selective residue substitution, isotope labeling, and conjugation handles. |
| Extended and Flexible Peptides | Linear or weakly ordered sequences enriched in residues that favor extended conformations, dynamic ensembles, or context-dependent folding. | Backbone modification, N-methylation, D-amino acid scanning, terminal capping, charge adjustment, lipid attachment, and stability-oriented analog design. |
| Cyclic and Constrained Peptides | Head-to-tail cycles, side-chain-to-side-chain rings, lactam bridges, disulfide cycles, stapled helices, and other conformationally restricted architectures. | Macrocyclic peptide synthesis, on-resin or solution cyclization, chemoselective ligation, disulfide folding, stapling, and ring-size optimization. |
| Branched and Multivalent Peptides | Dimeric, dendrimeric, multi-arm, or scaffolded constructs presenting repeated or different antimicrobial sequences from a defined branching core. | Orthogonal branch formation, lysine-core assembly, asymmetric sequence installation, spacer tuning, terminal functionalization, and controlled multivalent design. |
| Lipidated and Conjugated Peptides | Peptides linked to fatty acids, carbohydrates, polymers, carrier molecules, probes, nanoparticles, or other functional components. | Site-selective lipidation, glycosylation, PEGylation, labeling, linker installation, and custom peptide conjugation. |
Share your AMP sequence, desired modifications, quantity, and intended application. Our specialists will evaluate sequence complexity, recommend a synthesis route with appropriate protection and coupling strategies, and design a project-specific plan covering assembly, modification, folding, purification, and analytical characterization.
We review the target sequence, biological source, structural features, intended modification, required scale, purity target, and downstream research use. Peptide length, charge, hydrophobicity, cysteine content, expected folding, raw-material availability, and potential production challenges are assessed to define the project requirements.
A suitable production route is selected according to peptide origin, sequence complexity, structural requirements, modification needs, and project scale. Available approaches include chemical synthesis, recombinant expression, microbial fermentation, enzymatic production, and extraction or isolation from biological materials. Process design may cover protection chemistry, expression conditions, precursor cleavage, extraction, enrichment, folding, and initial purification.
The prepared peptide undergoes project-specific modification or conjugation, such as terminal capping, cyclization, lipidation, PEGylation, glycosylation, labeling, non-natural amino acid incorporation, or carrier attachment. Reaction conditions and modification sites are controlled to reduce unwanted products, followed by preparative HPLC or another suitable purification method.
Final material is evaluated using analytical HPLC and LC-MS testing, with sequence, disulfide connectivity, modification-site, or secondary-structure analysis added when required. Clients receive the antimicrobial peptide together with chromatographic and mass data, production and modification records, handling information, and project-specific documentation.
Long AMP sequences, sterically hindered residues, and stretches of hydrophobic amino acids frequently cause incomplete acylation during SPPS, leading to deletion products that are difficult to remove by standard purification. BOC Sciences addresses this by screening coupling reagents (HATU, HCTU, PyBOP), adjusting reaction time and temperature, applying microwave-assisted synthesis for difficult elongations, and monitoring coupling efficiency with real-time colorimetric tests. When necessary, we incorporate pseudoproline dipeptides or isoacyl dipeptide building blocks at aggregation-prone positions to improve solvation and coupling completeness, followed by purity determination at intermediate and final stages.
Many AMPs, especially those with high hydrophobic content or amphipathic helical character, aggregate on the resin during chain assembly or precipitate during cleavage and purification. This reduces crude purity, lowers recovery, and complicates HPLC fraction selection. BOC Sciences mitigates aggregation by evaluating resin loading density, introducing pseudoproline or Dmb-dipeptide units at identified aggregation sites, adjusting cleavage cocktail composition, and screening mobile phase conditions — including solvent composition, pH, and ion-pairing reagent — during reverse-phase chromatography services. For highly aggregation-prone peptides, we compare multiple purification strategies and buffer systems to identify conditions that maintain solubility while achieving target purity.
Disulfide-rich AMPs such as defensins and cyclotides present a folding challenge: a peptide with n cysteine residues can theoretically form multiple disulfide isomers, only one of which corresponds to the native bioactive conformation. BOC Sciences uses orthogonal cysteine protecting groups — such as Trt/Acm or Trt/tBu/Mmt combinations — to direct disulfide bond formation in a stepwise, regioselective manner. For cyclotides and cyclic AMPs, we evaluate on-resin versus solution-phase cyclization, monitor folding progress by analytical HPLC and MS testing, and compare folding yields across redox buffer systems to select the most efficient folding protocol for each sequence.
After synthesis and purification, AMP projects can suffer from low overall recovery due to cumulative losses at cleavage, workup, folding, and fraction collection steps. Product heterogeneity — including oxidized methionine species, aspartimide-derived byproducts, truncated sequences, and incomplete deprotection products — further reduces the yield of the target peptide. BOC Sciences improves recovery by optimizing each workflow step: evaluating cleavage and deprotection completeness, using volatile buffers compatible with lyophilization, monitoring aspartimide formation risk during piperidine treatments, and employing ion exchange chromatography (IEX) services as an orthogonal purification dimension when RP-HPLC alone provides insufficient resolution of closely related peptide species.
Collaborate with BOC Sciences to access custom antimicrobial peptide synthesis, structural modification, controlled folding, purification, and orthogonal characterization — all supported by application-oriented data packages for anti-infective drug discovery, SAR studies, and mechanism-of-action research.
Our team has synthesized hundreds of AMPs spanning all major structural classes — α-helical, β-sheet defensins, cyclic, lipopeptide, and extended coil — across a broad length range from short 8-mer sequences to 50-residue peptides. We routinely handle difficult features including multiple disulfide bonds, head-to-tail cyclization, N-terminal lipidation, and D-amino acid incorporation. This breadth of experience, combined with our analytical platform, means we can approach each new AMP project with established methods rather than trial-and-error experimentation.
We do not apply a single standard protocol to every AMP. Our chemists evaluate each sequence individually — considering hydrophobicity profile, cysteine spacing, modification sites, and aggregation risk — and select the appropriate resin, protecting group strategy, coupling chemistry, and cleavage conditions. For particularly challenging sequences, we compare multiple synthetic routes and provide data-driven recommendations before committing to full-scale synthesis.
BOC Sciences manages the entire AMP production process in a single coordinated workflow: SPPS assembly, post-synthetic modification (oxidation, cyclization, lipidation, or conjugation), preparative HPLC purification, and orthogonal characterization including NMR testing when needed for structural confirmation. This integration eliminates the delays, communication gaps, and sample handling risks that arise when synthesis and analysis are performed by separate providers, giving clients a single point of accountability.
Whether you need one purified AMP for initial activity screening or a focused library of 20–50 analogs for SAR analysis, BOC Sciences scales the project accordingly. For custom libraries and screening libraries, we apply parallel synthesis strategies, standardized purification protocols, and consistent analytical reporting across all library members, enabling reliable cross-compound comparison of purity, identity, and quantity for downstream biological testing.
Client Needs: A microbiology research group required a plant defensin analog — a 45-residue peptide with four disulfide bonds adopting the cysteine-stabilized αβ (CSαβ) motif — for antibacterial mechanism studies against methicillin-resistant Staphylococcus aureus (MRSA). The sequence contained eight cysteine residues with a conserved Cys1-Cys8, Cys2-Cys5, Cys3-Cys6, Cys4-Cys7 disulfide connectivity pattern. The client's previous attempt using random air oxidation produced a complex mixture of disulfide isomers with less than 10% of the correctly folded peptide.
Challenges: Achieving regioselective disulfide bond formation in a peptide with four overlapping disulfide bridges required precise control over cysteine deprotection and oxidation order. The hydrophobic core of the CSαβ motif also made the reduced linear precursor poorly soluble, complicating folding and purification. Additionally, the final folded peptide needed to retain antibacterial activity comparable to the native defensin, making correct disulfide connectivity essential rather than simply achieving any oxidized form.
Solution: We designed a stepwise regioselective folding strategy using orthogonal cysteine protection: Cys1 and Cys8 were protected as Trt, Cys2 and Cys5 as Acm, Cys3 and Cys6 as tBu, and Cys4 and Cys7 as Mmt. After SPPS assembly and cleavage, the first disulfide (Cys4-Cys7) was formed during Mmt removal with dilute TFA in the presence of an oxidizing scavenger. The second pair (Cys1-Cys8) was installed by controlled air oxidation at pH 8.0 with GSH/GSSG redox buffer, monitored by analytical HPLC across 6 time points. Acm groups on Cys2 and Cys5 were removed with iodine oxidation to form the third disulfide, followed by tBu deprotection of Cys3 and Cys6 and final DMSO-mediated oxidation. Each intermediate was purified by preparative HPLC and confirmed by MS. The fully folded peptide was analyzed by CD spectroscopy to verify the αβ-motif signature and tested in the client's MRSA membrane permeabilization assay, yielding activity within 85% of the native peptide benchmark.
Outcome: The client received 12 mg of correctly folded defensin analog (>95% purity) with documented disulfide connectivity, CD spectral confirmation, and a complete step-by-step folding protocol enabling reproducible in-house production of additional batches.
Client Needs: A biopharmaceutical team developing novel antifungal agents needed a focused library of 24 N-terminally lipidated magainin II analogs for SAR evaluation against azole-resistant Candida albicans and Candida auris. The library required systematic variation of fatty acid chain length (C8, C10, C12, C14, C16, C18) combined with four charge-modulating sequence variants, all at a consistent scale of 5 mg per analog with uniform purity specifications.
Challenges: The combination of a highly hydrophobic lipid anchor with the amphipathic magainin sequence created solubility difficulties during both coupling and purification. Longer-chain lipidated peptides (C16, C18) showed poor recovery during RP-HPLC and tended to form micelle-like aggregates in aqueous mobile phases. Maintaining consistent purity and recovery across all 24 library members required careful balancing of synthesis scale, purification conditions, and lyophilization parameters for each lipid chain length category.
Solution: We synthesized all 24 peptides on a 0.05 mmol scale using pre-loaded Wang resin, with the magainin II sequence assembled first and N-terminal Fmoc deprotection followed by on-resin acylation with the corresponding fatty acid activated as the NHS ester. For C14–C18 lipidated variants, we extended acylation time to 16 hours and monitored completion by Kaiser test before cleavage. Each crude peptide was purified by preparative RP-HPLC with a shallow acetonitrile gradient and elevated column temperature (40 °C) to improve resolution of the lipidated product from deletion sequences. For C16 and C18 variants, we added 10% isopropanol to the mobile phase to suppress aggregation during chromatography. All 24 peptides were analyzed by LC-MS for mass confirmation, HPLC for purity assessment, and quantified by UV absorbance at 280 nm. A subset of 8 representative analogs was further characterized by CD spectroscopy in SDS micelles to confirm α-helical content, and hemolytic activity was measured against human erythrocytes to establish selectivity indices for cross-library comparison.
Outcome: The client received the complete 24-peptide library with individual analytical data sheets, enabling direct SAR comparison. Several C12- and C14-lipidated analogs showed potent anti-Candida activity with favorable selectivity over mammalian cells, guiding the selection of lead candidates for further optimization.
BOC Sciences supports custom synthesis and production of antibacterial, antifungal, antiviral, and antiparasitic peptides. Projects may involve linear, α-helical, β-sheet, disulfide-rich, cyclic, branched, multivalent, lipidated, or conjugated structures. We can reproduce sequences originating from animals, plants, or microorganisms, as well as prepare chemically designed peptides and analog libraries. Support can include sequence variants, truncation series, D-amino acid analogs, labeled peptides, and peptides intended for anti-infective, food preservation, or biopesticide research. The exact scope is determined after sequence, feasibility, and route assessment.
The production route is selected according to sequence length, structural complexity, natural origin, modification requirements, desired scale, and material availability. Available approaches may include Fmoc- or Boc-based solid-phase peptide synthesis, fragment condensation, chemoselective ligation, recombinant expression, microbial fermentation, enzymatic production, and extraction or isolation from suitable biological materials. Some projects may combine routes, such as recombinant production followed by enzymatic cleavage, chemical modification, or conjugation. Because not every route is appropriate for every peptide, BOC Sciences performs a feasibility assessment before confirming the production and purification plan.
Available options include N-terminal acetylation, C-terminal amidation, D-amino acid or non-natural amino acid incorporation, lipidation, PEGylation, glycosylation, cyclization, stapling, controlled disulfide formation, fluorescent or affinity labeling, isotope labeling, and conjugation to carriers or other functional components. Modification sites and installation order are selected according to peptide sequence, reactive residues, folding requirements, solubility, and downstream use. BOC Sciences can also prepare matched unmodified controls and focused modification series to help researchers compare how structural changes influence peptide properties and experimental performance.
Each difficult sequence is reviewed for charge, hydrophobicity, repeated residues, steric hindrance, aggregation-prone regions, oxidation-sensitive residues, cysteine connectivity, and expected folding. Chemical routes may be adjusted through resin selection, reduced loading, stronger or repeated coupling, backbone protection, pseudoproline units, fragment ligation, or staged disulfide formation. Biological routes may require changes to expression format, precursor design, cleavage, extraction, or enrichment. Purification conditions are then adapted to product solubility and impurity behavior. Analytical HPLC and mass spectrometry are used to guide route refinement and fraction selection.
Please provide the target amino acid sequence or source information, desired termini, disulfide pattern, cyclization format, modification or conjugation sites, required scale, purity target, preferred final form, and intended research application. If a biological production or extraction route is preferred, include the source organism or material, available construct or sample information, and any processing constraints. Reference structures, known solubility issues, previous synthesis attempts, and planned analytical or activity studies are also useful. BOC Sciences uses these details to assess feasibility, identify major technical risks, and recommend an appropriate production, purification, and characterization workflow.
We had a 38-residue defensin analog with three disulfide bonds that several providers declined due to folding complexity. BOC Sciences designed a regioselective cysteine protection strategy, executed the synthesis, and delivered correctly folded peptide with clear folding verification data. The entire process was transparent and the peptide performed well in our bacterial membrane depolarization assays.
— Dr. Perkins, Principal Investigator, Host Defense Peptide Laboratory
For our SAR study, we needed 30 magainin analogs with systematic single-residue substitutions. BOC Sciences delivered all 30 peptides with consistent purity and quantity, accompanied by individual HPLC and MS reports. The batch-to-batch consistency allowed us to confidently attribute activity differences to sequence changes rather than product quality variation.
— Dr. Blackwell, Senior Scientist, Antimicrobial Drug Discovery
The analytical data package we received — HPLC chromatograms, high-resolution mass spectra, and CD spectroscopy results — was thorough and well-organized. The documentation made it straightforward to include the peptide characterization data in our manuscript submission, and the reviewers commented positively on the quality of the synthetic peptide characterization.
— Dr. Petersen, Research Fellow, Biochemistry and Molecular Biology
When our initial lipidated peptide showed aggregation during purification, BOC Sciences promptly evaluated alternative mobile phase conditions and column temperatures, sharing HPLC traces and recovery data at each iteration. The proactive problem-solving approach and regular updates gave us confidence throughout the project, and the final product met our target specifications.
— Schmidt, Project Lead, Antifungal Peptide Development
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
